Merck used ghostwriters and selective data in Vioxx publications, JAMA says

doi:10.1136/bmj.39553.344965.DB

From trainee to consultant, BMJ Group offers doctors around the world tailored information, special events, learning resources and recruitment services at every step along their career path.

... by doctors, for doctors, for patients
We are open for entries!

Online learning

BMJ Learning

High-quality CME / CPD for doctors and other healthcare professionals. BMJ Learning features hundreds of accredited, peer-reviewed learning modules in text, video, and audio formats. Find out more

Courses and Qualifications

BMJ Masterclasses

BMJ Masterclasses, led by experts, help clinicians to use the latest evidence and recent guidelines in practice and meet their CPD/CME requirements. Find out more

Exam Preparation

The leading provider of online exam preparation, helping over 167,000 healthcare professionals to pass their exams. Find out more

onExamination

Search all BMJ news articles:

From

The BMJ iPad app brings you the best of print and online, including live links to the latest news, blogs, video, and podcasts. Get the BMJ iPad app.
Countdown to London 2012: BMJ Group's Olympics portal highlights latest Olympics and sports medicine-themed research, comment and learning
Keep up to date with cardiology: Access the latest cardiovascular medicine resources from across BMJ Group.
Our online table of contents is updated at least twice each day. Read all articles published in the last 7 days.
OPEN ACCESS: All research articles are freely available online, with no word limit. Find out more about the BMJ's open access policy. Submit your paper.

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

Janice Hopkins Tanne

¹New York

Researchers and editors claim in two papers and an editorial this week that Merck, the makers of the arthritis drug rofecoxib (Vioxx), misrepresented study results and used ghostwriters to prepare manuscripts for journal publication.

The authors of the articles have drawn their evidence from thousands of documents released during lawsuits against Merck over adverse events related to the drug (JAMA 2008;299:1800-12, 1813-7, and 1833-5).

Rofecoxib was withdrawn worldwide in September 2004 after a study showed that it doubled the risk of heart attack or stroke if it was taken for more than 18 months (BMJ 2004;329:816; doi: 10.1136/bmj.329.7470.816-a).

Merck said in a statement that it “believes that many of the comments in a Journal of the American Medical Association (JAMA) news release and in the 16 April 2008 issue of JAMA related to Vioxx are false, misleading, or lack context.”

The statement said, “The articles, based on analyses of documents conducted by consultants hired by trial lawyers as part of their work in the Vioxx product liability litigation, make allegations similar to …